News brief­ing: Mer­ck’s Roger Perl­mut­ter buys his first sol­id tu­mor TriN­KET from Drag­on­fly; Vi­Gen­eron to ex­pand pro­duc­tion of eye gene ther­a­py

A lit­tle more than 2 years af­ter Mer­ck’s Roger Perl­mut­ter signed off on a deal that would pay Drag­on­fly up to $695 mil­lion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.